Compare Raymond James Financial, Inc. (RJF) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Raymond James Financial, Inc. trades at $159.62 (market cap $30.51B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.69 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RJF | TAK | |
|---|---|---|
Market Cap | $30.51B | $58.74B |
Volume | 1,206,253 | 3,110,994 |
Sector | Financials | Health |
52-Week High | $181.18 | $19.05 |
52-Week Low | $140.89 | $13.23 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $24.37B | $86.65B |
Dividend Yield | 1.36% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $157.29, down 1.4% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 forecast. Revenue growth is steady, reaching $13.84 billion in 2025, while profitability remains strong with a net income margin of 15.37%. Recent corporate news includes executive leadership appointments and a declared quarterly dividend of $0.54 per share.
The outlook is mixed, with a consensus analyst price target of $184.00 suggesting upside potential, but technical indicators signal near-term caution. Key risks include rising expenses and capital market volatility. The absence of sell ratings and solid institutional interest support a fundamentally sound investment case, though investors should weigh the bearish technical momentum against strong fundamentals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
